Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Eliquis

Roche Basel Switzerland

Roche prepares to file atezolizumab for bladder cancer

Imminent submission to the FDA after additional positive phase II trial results

- PMLiVE

Keytruda bounces back in rivalry with Opdivo

First drug in its class to secure FDA approval as a first-line therapy for malignant melanoma

- PMLiVE

ViiV agrees $1.5bn deal to acquire BMS’ HIV assets

Includes its entire development pipeline - from discovery to preclinical projects

- PMLiVE

NHS patients set to be denied Opdivo and Kadcyla

NICE rejects BMS and Roche cancer treatments

- PMLiVE

BMS’ Empliciti approved by FDA for multiple myeloma

Clearedfor use in with Celgene's Revlimid and corticosteroid dexamethasone

Bristol-Myers Squibb (BMS) building

Bump in the road slows momentum for BMS’ Opdivo

FDAturns down the cancer treatment for a form of melanoma

Bristol-Myers Squibb (BMS) building

Opdivo cleared for kidney cancer and first-line melanoma

First drug to show survival benefit in kidney cancer since 2007

Bristol-Myers Squibb (BMS) building

BMS closer to kidney cancer approval for Opdivo

Wins priority review for renal cell carcinoma

Bristol-Myers Squibb (BMS) building

BMS agrees to buy Cardioxyl for heart failure drug

Willpay up to $2bn for the US-based company

Bristol-Myers Squibb (BMS) building

BMS’ Yervoy receives additional FDA approval

Gives the nod for Yervoy as adjuvant treatment option for melanoma

Bristol-Myers Squibb (BMS) building

BMS pulls ahead of Merck in quarterly PD-1 inhibitor sales

Supports analysts prediction BMS' Opdivo will become market leader

Bristol-Myers Squibb (BMS) building

First data backs efficacy of BMS’ novel HIV drug

Could provide new treatment for those resistant to antiretroviral therapy

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links